
Kent Lake Urges Fellow Quanterix Shareholders To Vote “AGAINST” The Dilutive, Risky Merger With Akoya Biosciences, Which Undervalues Quanterix’s Standalone Potential
The proposed merger devalues Quanterix and disproportionately benefits Akoya at Quanterix shareholders' expense.
The deal effectively bails out Akoya, introduces unnecessary financial and operational risks, and diverts critical cash and management attention away from Quanterix’s biggest growth opportunity: Alzheimer’s diagnostic expansion.
Quanterix stockholders deserve better than this value destructive Merger.
As such, we respectfully urge stockholders to vote “AGAINST” the Merger to preserve the Company’s clear and compelling path toward long-term value creation.
READ OUR INVESTOR PRESENTATION
ABOUT KENT LAKE
Kent Lake initially invested in Quanterix in 2022 and is currently a top three shareholder…
REASONS TO VOTE AGAINST
Kent Lake believes the proposed merger significantly undervalues Quanterix, is a shareholder-funded bailout of Akoya, and would introduce significant unnecessary risk to Quanterix’s balance sheet…
HOW TO VOTE
Kent Lake intends to file a preliminary proxy statement and accompanying GOLD universal proxy card with the SEC…
INVESTOR CONTACT
Kent Lake PR
Ben Natter
415-237-0007
Info@kentlakecap.com
Saratoga Proxy Consulting LLC
John Ferguson / Ann Marie Mellone
212-257-1311 / 888-368-0379
Info@saratogaproxy.com
MEDIA CONTACT
Longacre Square Partners
Joe Germani / Kendall Heebink
KentLake@longacresquarepartners.com